Wydanie specjalne czerwiec 2017
str. 36 - 39
Leczenie afliberceptem chorych na neowaskularną postać zwyrodnienia plamki związanego z wiekiem w ramach programu lekowego – opis przypadków
Treatment of Neovascular Age-related Macular Degeneration Using Aflibercept as a part of the National Health Fund Drug Prescription Program – Case Series
Samodzielny Publiczny Kliniczny Szpital Okulistyczny w Warszawie
Summary: Age-related macular degeneration, especially its neovascular form, is still the leading cause of irreversible vision loss in elderly in developed countries. According to the new reimbursement schedule, National Drug Program, Polish patients with neovascular form of age-related macular degeneration are treated with aflibercept in the proactive scheme or ranibizumab in the reactive scheme.
The authors present five cases of neovascular form age-related macular degeneration patients treated with aflibercept and discussion of outcomes. In 3 cases of patients with quick qualification to the program both, the vision and clinical features of the disease, significantly improved. The 4th patient had progression of neovascular form age-related macular degeneration probably due to the concomitant acute venous thrombosis and necessity of antithrombotic treatment. The 5th patient with long period of symptoms of neovascular form age-related macular degeneration experienced vision deterioration as well as fundus abnormalities.
In conclusion, drug program seems to give more opportunities to stabilize or improve vision of neovascular form age-related macular degeneration patients. The crucial issue is the short time of symptoms and quick path of diagnosis and treatment. Although drug program’s inclusion criteria are rather wide, some individual cases with potential good prognosis are still out of limit.
Słowa kluczowe: zwyrodnienie plamki związane z wiekiem (AMD), iniekcja doszklistkowa, aflibercept.
Keywords: age-related macular degeneration (AMD), intravitreal injection, aflibercept.